Whitepaper

Enabling Acceleration & Risk Mitigation in Advanced Therapy Medicinal Product (ATMP) Development & Beyond

July 23, 2024
Enabling-Acceleration-LP

In the evolving landscape of Advanced Therapy Medicinal Products (ATMPs), the potential to address a multitude of diseases, including rare disorders, is underscored by significant advancements.
 
With 17 gene therapies approved in the United States in 2023 and anticipation of a breakout year in 2024 for cell and gene therapies, particularly targeting rare disorders, the urgency to overcome hurdles is evident (Source: https://alliancerm.org/arm-event/sotibriefing/). Embracing proactive risk mitigation strategies and fostering collaborative ecosystems are essential to propel the translation of scientific discoveries into transformative therapies, shaping a brighter future for medicine and patient care.
 
In Azzur Group's new whitepaper, you will gain an understanding of dynamic solutions to help navigate manufacturing complexities and accelerate ATMP development.

Related Insights
From Discovery To Delivery™